Orna Therapeutics, a biotechnology company dedicated to RNA therapeutics (oRNAs), announced the completion of its $80 million Series A financing. The firm was founded on groundbreaking research from the Massachusetts Institute of Technology (MIT) and built by MPM Capital.

The financing was co-led by MPM Capital, Taiho Ventures, and F2 Ventures, with participation from leading strategic investors: Kite, a Gilead Company, Bristol Myers Squibb, Astellas Venture Management, Novartis Institutes for Biomedical Research, and the PAGS Group.

Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way disease is treated. Orna's proprietary platform combines novel technology to create oRNAs that drive protein expression with validated and unique delivery solutions. oRNA has many advantages over traditional mRNA approaches, including simplified production, improved formulatability, and superior protein expression - making it a highly disruptive, new class of RNA therapeutics with vast potential to change patient's lives.